Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 103.68B |
| Revenue (ttm) | 45.17B |
| Net Income (ttm) | 6.30B |
| Shares Out | 1.22B |
| EPS (ttm) | 5.04 |
| PE Ratio | 17.09 |
| Forward PE | 10.45 |
| Dividend | 3.92 (4.60%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 906,901 |
| Average Volume | 1,509,212 |
| Open | 84.87 |
| Previous Close | 85.22 |
| Day's Range | 84.68 - 85.56 |
| 52-Week Range | 81.50 - 110.88 |
| Beta | 0.40 |
| RSI | 54.99 |
| Earnings Date | Jul 31, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi gets EU nod for Sarclisa combination in multiple myeloma
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction t...
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Sanofi's Beyfortus injection succeeds in US study
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Daniel...
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.
Sanofi’s $2.5b deal to buy biotech with rights to Aussie vaccine invention
Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology invented at the University of Queensland.
Sanofi Acquires Vicebio in $1.6 Billion Deal
Sanofi Acquires Vicebio in $1.6 Billion Deal
Sanofi to acquire Vicebio in $1.6 billion deal to boost respiratory portfolio
France's Sanofi to acquire biotech firm Vicebio for $1.15 bln
French pharmaceuticals company Sanofi said on Tuesday it agreed to acquire British private biotechnology firm Vicebio for a total of $1.15 billion, in a bid to expand its respiratory vaccines portfoli...
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held bi...
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfol...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Daniel...
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.
Thermo Fisher Scientific to buy Sanofi production site in New Jersey
Emcure and Sanofi India announce exclusive partnership to distribute oral anti-diabetic drugs in India
Emcure Pharmaceuticals Ltd. and Sanofi India Ltd. (SIL) have announced an exclusive distribution and promotion agreement for Sanofi’s oral anti-diabetic (OAD) products in India, effective immediately....
Press Release: Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi: A Solid EU Contrarian Play
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil...
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook
Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. (NYSE: PFE). The company will announce second-quarter 2025 earnings on August 5 . According to data from Benzinga Pro , an...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Daniell...
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, c...
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck & Co. Inc. (NYSE: MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ: VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle...